Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: Cacaito who wrote (15865)	6/21/2002 11:23:10 AM
From: Robert K.	Read Replies (1) \| Respond to of 17367

I think hu-1124 has uses more numerous to remember. I think the same "still" of bpi. What continues to trouble me the most with this company is the lack of commitment to bpi and analogs. Baxter for its part may run with bpi or might cut loose if no earlyt success. Xoma for its part has a "lower the profile" attitude and why they dont persue bpi as a antifungal is beyond belief. Xoma has major intellectual property with bpi & biotech processes. I continue to wait and hope for the attention bpi deserves. Bpi works, proving it is still another matter. NIce to see some old faces here. I lurk and wait and still have my bigfoot in the doorway. Cacaito>agree 100%, newborn deficiency shoulda been agressively persued. Regarding hu-1124, psoriasis is not most important, there are too many other indications. What is important is getting it on market. Another deep concern of mine is the dna convertable debt issue in 2005.